1. Dray, A. & Perkins, M. Bradykinin and inflammatory pain. Trends Neurosci. 16, 99–104 (1993).
2. Waeber, B. & Brunner, H. R. Cardiovascular hypertrophy: role of angiotensin II and bradykinin. J. Cardiovasc. Pharmacol. 27, S36–S40 (1996).
3. Tomita, H., Sanford, R. B., Smithies, O. & Kakoki, M. The kallikrein-kinin system in diabetic nephropathy. Kidney Int. 81, 733–744 (2012).
4. Marceau, F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 3, 845–852 (2004).
5. Marceau, F. et al. Bifunctional ligands of the bradykinin B2 and B1 receptors: an exercise in peptide hormone plasticity. Peptides 105, 37–50 (2018).
6. Garvin, M. R. et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 9, e59177 (2020).
7. Zwaveling, S., Gerth van Wijk, R. & Karim, F. Pulmonary edema in COVID-19: explained by bradykinin? J. Allergy Clin. Immunol. 146, 1454–1455 (2020).
8. van de Veerdonk, F. L. et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9, e57555 (2020).
9. McEachern, A. E. et al. Expression cloning of a rat B2 bradykinin receptor. Proc. Natl Acad. Sci. USA 88, 7724–7728 (1991).
10. Surgand, J. S., Rodrigo, J., Kellenberger, E. & Rognan, D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62, 509–538 (2006).
11. Bastian, S., Loillier, B., Paquet, J. L. & Pruneau, D. Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization. Br. J. Pharmacol. 122, 393–399 (1997).
12. Hess, J. F. et al. Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol. Pharmacol. 45, 1–8 (1994).
13. Leeb-Lundberg, L. M., Marceau, F., Muller-Esterl, W., Pettibone, D. J. & Zuraw, B. L. International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharm. Rev. 57, 27–77 (2005).
14. Meini, S. et al. Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem. Pharmacol. 67, 601–609 (2004).
15. Lupala, C. S., Gomez-Gutierrez, P. & Perez, J. J. New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding. J. Mol. Graph. Model. 68, 184–196 (2016).
16. Lupala, C. S., Gomez-Gutierrez, P. & Perez, J. J. New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding. J. Comput. Aided Mol. Des. 30, 85–101 (2016).
17. Lopez, J. J. et al. The structure of the neuropeptide bradykinin bound to the human G-protein coupled receptor bradykinin B2 as determined by solid-state NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 47, 1668–1671 (2008).
18. Joedicke, L. et al. The molecular basis of subtype selectivity of human kinin G-protein-coupled receptors. Nat. Chem. Biol. 14, 284–290 (2018).
19. Rasaeifar, B., Lupala, C. S., Gomez-Gutierrez, P. & Perez, J. J. Molecular features characterizing non-peptide selectivity to the human B1 and B2 bradykinin receptors. Bioorg. Med. Chem. Lett. 29, 11–14 (2019).
20. Duan, J. et al. Cryo-EM structure of an activated VIP1 receptor-G
